Your browser doesn't support javascript.
loading
Recombinant human interferon-α1b inhibits SARS-CoV-2 better than interferon-α2b in vitro.
Shi, Danrong; Chen, Keda; Lu, Xiangyun; Cheng, Linfang; Weng, Tianhao; Liu, Fumin; Wu, Nanping; Li, Lanjuan; Yao, Hangping.
Afiliación
  • Shi D; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
  • Chen K; Shulan International Medical College, Zhejiang Shuren University, Hangzhou, 310015, China.
  • Lu X; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
  • Cheng L; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
  • Weng T; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
  • Liu F; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
  • Wu N; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China. Electronic address: flw
  • Li L; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China. Electronic address: ljl
  • Yao H; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China. Electronic address: yao
Virol Sin ; 37(2): 295-298, 2022 04.
Article en En | MEDLINE | ID: mdl-35597770
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: SARS-CoV-2 / Tratamiento Farmacológico de COVID-19 Límite: Humans Idioma: En Revista: Virol Sin Asunto de la revista: VIROLOGIA Año: 2022 Tipo del documento: Article País de afiliación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: SARS-CoV-2 / Tratamiento Farmacológico de COVID-19 Límite: Humans Idioma: En Revista: Virol Sin Asunto de la revista: VIROLOGIA Año: 2022 Tipo del documento: Article País de afiliación: China